Bolar/NNP Pharmaceutical/NNP Co./NNP ,/, under/IN pressure/NN from/IN the/DT Food/NNP and/CC Drug/NNP Administration/NNP ,/, agreed/VBD to/TO recall/VB its/PRP$ generic/JJ version/NN of/IN the/DT antibiotic/JJ drug/NN Macrodantin/NNP from/IN retail/JJ shelves/NNS ,/, according/VBG to/TO FDA/NNP officials/NNS ./.
It/PRP was/VBD another/DT setback/NN for/IN Bolar/NNP ,/, the/DT flagship/NN of/IN the/DT generic/JJ drug/NN industry/NN ./.
this/DT month/NN ,/, Bolar/NNP began/VBD recalling/VBG its/PRP$ nitrofurantoin/NN macrocrystalline/NN capsules/NNS from/IN wholesalers/NNS and/CC distributors/NNS because/RB of/IN FDA/NNP evidence/NN suggesting/VBG that/IN the/DT company/NN passed/VBN off/IN Macrodantin/NNP as/IN its/PRP$ own/JJ to/TO obtain/VB FDA/NNP approval/NN to/TO market/VB its/PRP$ generic/JJ product/NN ./.
that/DT time/NN ,/, however/RB ,/, the/DT company/NN balked/VBD at/IN a/DT retail/JJ recall/NN ,/, arguing/VBG that/IN the/DT evidence/NN was/VBD n't/RB sufficient/JJ to/TO justify/VB such/PDT a/DT move/NN ./.
Oct./NNP 25/CD ,/, the/DT FDA/NNP offered/VBD additional/JJ evidence/NN to/TO buttress/VB its/PRP$ case/NN that/IN the/DT brand-name/JJ drug/NN had/VBD been/VBN substituted/VBN for/IN Bolar/NNP 's/POS product/NN in/IN pre-market/JJ testing/NN ,/, FDA/NNP officials/NNS said/VBD yesterday/NN ./.
The/DT agency/NN now/RB has/VBZ evidence/NN that/IN Bolar/NNP submitted/VBD Macrodantin/NNP as/IN its/PRP$ generic/JJ version/NN for/IN testing/VBG|NN not/RB only/RB at/IN PharmaKinetics/NNP Laboratories/NNP Inc./NNP ,/, Baltimore/NNP ,/, but/CC also/RB at/IN an/DT independent/JJ laboratory/NN in/IN Canada/NNP ./.
FDA/NNP investigators/NNS obtained/VBD a/DT sample/NN of/IN the/DT Bolar/NNP drug/NN from/IN the/DT Canadian/JJ lab/NN ,/, according/VBG to/TO FDA/NNP official/NN Michael/NNP Shaffer/NNP ./.
It/PRP turned/VBD out/RP to/TO be/VB the/DT brand-name/JJ product/NN ,/, ''/'' he/PRP said/VBD ./.
Copiague/NNP ,/, N.Y./NNP ,/, Robert/NNP Shulman/NNP ,/, president/NN of/IN Bolar/NNP ,/, and/CC sales/NNS director/NN Karen/NNP Sattig/NNP could/MD n't/RB be/VB reached/VBN for/IN comment/NN ./.
The/DT inspector/NN general/JJ 's/POS office/NN of/IN the/DT Health/NNP and/CC Human/NNP Services/NNP Department/NNP already/RB is/VBZ conducting/VBG a/DT criminal/JJ investigation/NN of/IN whether/IN Bolar/NNP filed/VBD ``/`` false/JJ information/NN ''/'' with/IN the/DT FDA/NNP in/IN seeking/VBG clearance/NN to/TO market/NN at/IN least/JJS two/CD generic/JJ drugs/NNS ./.
the/DT FDA/NNP is/VBZ moving/VBG to/TO withdraw/VB its/PRP$ approval/NN of/IN Bolar/NNP  's/POS nitrofurantoin/NN macrocrystalline/NN capsules/NNS ,/, which/WDT are/VBP used/VBN primarily/RB to/TO treat/VB urinary-tract/NN infections/NNS ./.
The/DT brand-name/JJ drug/NN is/VBZ manufactured/VBN by/IN Norwich/NNP Eaton/NNP ,/, a/DT subsidiary/NN of/IN Cincinnati-based/JJ Procter/NNP &/CC Gamble/NNP Co/NNP ./.
no/DT health/NN problems/NNS are/VBP known/VBN to/TO have/VB been/VBN caused/VBN by/IN Bolar/NNP  's/POS product/NN ,/, the/DT FDA/NNP officials/NNS said/VBD the/DT agency/NN can/MD no/RB longer/RBR ensure/VB that/IN it/PRP is/VBZ the/DT equivalent/NN of/IN Macrodantin/NNP ./.
American/NNP Stock/NNP Exchange/NNP composite/JJ trading/NN yesterday/NN ,/, Bolar/NNP closed/VBD at/IN $/$ 14.375/CD ,/, down/RB 50/CD cents/NNS ./.
